Celcuity shares rise on US launch of breast cancer drug Revtorpyk
Shares of drugmaker Celcuity rose 4.11% to $80.56 premarket after the company announced its FDA-approved breast cancer drug Revtorpyk is now commercially available in the US. The drug is approved with fulvestrant for certain patients with advanced breast cancer whose tumours do not have a PIK3CA gene mutation and whose